Related Experiment Video

Updated: Aug 16, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Monoamine oxidase, dopamine and Parkinson's disease

L Oreland1

  • 1Department of Medical Pharmacology, University of Uppsala, Sweden.

Acta Neurologica Scandinavica. Supplementum
|January 1, 1991
PubMed

Insights

Monoamine oxidase (MAO) B is crucial for dopamine deamination in Parkinson's disease. This review examines MAO's role, kinetics, and involvement in disease processes, particularly concerning L-deprenyl treatment.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Parkinson's disease is a neurodegenerative disorder affecting dopamine pathways.
  • Monoamine oxidase (MAO) enzymes play a critical role in neurotransmitter metabolism.
  • L-deprenyl, a selective MAO-B inhibitor, is used in Parkinson's disease treatment.

Purpose of the Study:

  • To review the significance of MAO-A and MAO-B in dopamine deamination.
  • To discuss the kinetics of MAO, including recovery after irreversible inhibition.
  • To explore MAO's potential changes and role in Parkinson's pathophysiology.

Main Methods:

  • Literature review of MAO's role in dopamine metabolism.
  • Analysis of MAO kinetics and enzyme recovery post-inhibition.
  • Examination of MAO's involvement in Parkinson's disease pathogenesis.

Main Results:

  • MAO-B is particularly important for dopamine deamination, especially within dopaminergic nerve terminals.
  • Understanding MAO enzyme kinetics is vital for optimizing L-deprenyl therapy.
  • MAO activity may be altered by and contribute to Parkinson's disease progression.

Conclusions:

  • MAO-B's role in dopamine metabolism is central to Parkinson's disease.
  • MAO kinetics and its pathological involvement are key considerations for L-deprenyl treatment efficacy.
  • Further research into MAO's dynamic role in Parkinson's disease is warranted.

More Related Videos

Primary Culture of Mouse Dopaminergic Neurons11:58

Primary Culture of Mouse Dopaminergic Neurons

Published on: September 8, 2014

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...